coronary artery bypass grafting

Long-Term Comparative Outcomes of Bilateral versus Single Internal Thoracic Artery Grafts in Coronary Bypass Surgery

By MedXY 09/06/2026

This analysis of a randomized trial finds no survival benefit at 15 years for bilateral versus single internal thoracic artery grafting in coronary bypass surgery, highlighting the need for further trials to clarify the multiple arterial graft hypothesis.

Cardiology General Surgery news

Expedited Discharge After Isolated Coronary Artery Bypass Grafting: Impacts on Hospital Stay and Patient Outcomes

By MedXY 08/09/2026

Expedited discharge (≤4 days) following isolated coronary artery bypass grafting is linked to shorter hospital stays, lower costs, and reduced 30-day readmissions without increased mortality or major complications, supporting selective implementation of accelerated recovery protocols.

Cardiology news

Multiarterial Grafting and Survival After Coronary Artery Bypass Grafting: An Instrumental Variable Analysis

By MedXY 05/19/2026

In a large Medicare study, multiarterial grafting after CABG looked beneficial in standard analysis, but the advantage disappeared with instrumental variable adjustment, suggesting earlier observational studies may have overestimated survival benefit.

Cardiology Clinical Updates news

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis

By MedXY 12/18/2025

This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinical practice.

Cardiology news

Reevaluating New-Onset Atrial Fibrillation After CABG: Insights from Long-Term Continuous Monitoring

By MedXY 10/10/2025

A multicenter prospective study reveals a higher incidence but very low burden of new-onset atrial fibrillation post-CABG, challenging current anticoagulation guidelines.

Cardiology news Specialties

Evolocumab and Saphenous Vein Graft Patency Post-CABG: Insights from the NEWTON-CABG Trial

By MedXY 09/21/2025

The NEWTON-CABG CardioLink-5 trial found that intensive LDL-C lowering with evolocumab did not improve saphenous vein graft patency 24 months after coronary artery bypass surgery despite significant LDL-C reductions.